Could Patient Stratification Help Lilly Finally Unlock An Alzheimer’s Breakthrough?

Tau Status Stratification Unique To Lilly Trial

Lilly believes its approach can help identify the Alzheimer’s patients who would benefit most from a beta amyloid clearing therapy – but skepticism about the mechanism itself remains widespread.

Eli Lilly logo sign atop Lilly Biotechnology Center
Lilly's TRAILBLAZER 2 will be the last of the three competitor trials to read out, in mid-2023. • Source: Michael Vi / Shutterstock.com

As the readouts from three late-stage Alzheimer’s disease drug candidates draw nearer, hopes are again rising that a breakthrough may finally be possible – but given the string of failures over the last 20 years, many are skeptical about the chances of success for the beta-amyloid targeting antibody therapies.

Eli Lilly believes its patient-stratification approach could give it the edge, but its readout looks set to be the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip